NCT05054725 2026-01-06
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Phase 2 Completed
Revolution Medicines, Inc.
Medical University of South Carolina
Amgen
Amgen
Vitrac Therapeutics, LLC
Amgen